Description
Uses of Romiplostim injections Medicine:
Romiplostim injections is a thrombopoietin receptor agonist utilized for the treatment of thrombocytopenia in:
- Adult patients with Immune Thrombocytopenia (ITP): Recommended for those who have not responded sufficiently to corticosteroids, immunoglobulins, or splenectomy.
- Pediatric patients (aged 1 year and older) with ITP: Suitable for children with ITP for at least six months, who have shown an inadequate response to corticosteroids, immunoglobulins, or splenectomy.
- Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS): Approved for improving survival in adults and pediatric patients, including neonates, exposed to myelosuppressive doses of radiation.
Limitations of Use:
- Romiplostim is not indicated for patients with thrombocytopenia due to myelodysplastic syndrome (MDS) or other causes unrelated to ITP.
- This medication should only be prescribed to ITP patients where the condition and severity of thrombocytopenia increase bleeding risk.
- Romiplostim should not be used to normalize platelet counts.
Dosage & Side Effects:
For Immune Thrombocytopenia (ITP): The initial dose of Romiplostim is 1 mcg/kg administered weekly via subcutaneous (SC) injection. The dose may be adjusted depending on the patient’s platelet response.
For Acute Radiation Exposure (HSARS): A single dose of 10 mcg/kg is recommended via subcutaneous (SC) injection, administered as soon as possible after suspected or confirmed radiation exposure.
In Adults: Frequently reported side effects include joint pain, dizziness, limb pain, trouble sleeping, abdominal pain, muscle aches, shoulder pain, indigestion, and tingling sensations.
In Children: Common side effects include bruising, throat pain, and upper respiratory infections.